

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

## SECTION 1. IDENTIFICATION

Product name : Timolol / Dorzolamide Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor  
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

## SECTION 2. HAZARDS IDENTIFICATION

**GHS Classification**

Specific target organ toxicity - repeated exposure : Category 1 (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs)

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.**Response:**

P314 Get medical advice/ attention if you feel unwell.

**Disposal:**

P501 Dispose of contents/ container to an approved waste

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Dorzolamide	130693-82-2	$\geq 1$ - $< 5$
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	$\geq 0,1$ - $< 1$

**SECTION 4. FIRST AID MEASURES**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion prod-	: Carbon oxides

**Timolol / Dorzolamide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

ucts		Nitrogen oxides (NO <sub>x</sub> ) Sulfur oxides Hydrogen chloride
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

## Timolol / Dorzolamide Formulation

Version 5.13      Revision Date: 30.09.2023      SDS Number: 28787-00021      Date of last issue: 04.04.2023  
 Date of first issue: 06.11.2014

- Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Dorzolamide	130693-82-2	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: Eye				
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: Eye, Skin				
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

## Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

**Timolol / Dorzolamide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

- Skin and body protection : Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hygiene measures : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- Appearance : liquid
- Color : colorless
- Odor : No data available
- Odor Threshold : No data available
- pH : 5,6
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available
- Evaporation rate : No data available
- Flammability (solid, gas) : Not applicable
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapor pressure : No data available
- Relative vapor density : No data available

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

Relative density	:	1,02
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
---------------------	---	--

**Components:****Dorzolamide:**

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

Acute oral toxicity : LD50 (Rat): 1.927 mg/kg  
LD50 (Mouse): 1.320 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Acute oral toxicity : LD50 (Rat): 1.000 mg/kg  
LD50 (Mouse): 1.140 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): 300 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): 800 mg/kg  
Application Route: Subcutaneous

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Dorzolamide:**

Species : Monkey  
Result : Mild eye irritation

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species : Rabbit  
Result : Mild eye irritation

Species : Dog  
Result : No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

**Components:****Dorzolamide:**

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	Weak sensitizer

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Dorzolamide:**

Genotoxicity in vitro	:	Test Type: Chromosomal aberration
		Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo	:	Test Type: Cytogenetic assay
		Species: Mouse
		Result: negative

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Method: OECD Test Guideline 471
		Result: negative

Genotoxicity in vivo	:	Test Type: In vivo micronucleus test
		Species: Mouse
		Method: OECD Test Guideline 474
		Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Dorzolamide:**

Species	:	Rat, male
Application Route	:	Oral
Exposure time	:	2 Years
	:	20 mg/kg body weight
Result	:	negative
Remarks	:	The mechanism or mode of action may not be relevant in hu-

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

---

mans.

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	21 month(s)
Result	:	negative

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
LOAEL	:	300 mg/kg body weight
Result	:	negative
Target Organs	:	Adrenal gland
Remarks	:	The significance of these findings for humans is not certain.

Species	:	Mouse, female
Application Route	:	Oral
Exposure time	:	18 Months
LOAEL	:	500 mg/kg body weight
Result	:	negative
Target Organs	:	Lungs, Mammary gland, Uterus (including cervix)
Remarks	:	The significance of these findings for humans is not certain.

Carcinogenicity - Assessment	:	Weight of evidence does not support classification as a carcinogen
------------------------------	---	--

**Reproductive toxicity**

Not classified based on available information.

**Components:****Dorzolamide:**

Effects on fertility	:	Test Type: Fertility Species: Rat, male and female Application Route: Oral Fertility: NOAEL: 7,5 mg/kg body weight Result: Animal testing did not show any effects on fertility.
----------------------	---	--

Effects on fetal development	:	Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 1 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses  Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 2,5 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
------------------------------	---	--

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight  
Early Embryonic Development: NOAEL F1: 150 mg/kg body weight
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit  
Developmental Toxicity: LOAEL F1: 50 mg/kg body weight  
Result: Some evidence of adverse effects on development, based on animal experiments.
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

**Product:**

- Target Organs : Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs
- Assessment : Causes damage to organs through prolonged or repeated exposure.

**Components:****Dorzolamide:**

- Target Organs : Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder
- Assessment : May cause damage to organs through prolonged or repeated exposure.

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

- Target Organs : Lungs, Cardio-vascular system
- Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Dorzolamide:**

- Species : Rat
- NOAEL : 0,05 mg/kg
- Application Route : Oral
- Target Organs : Bladder, Kidney
- Species : Dog

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

NOAEL : 0,05 mg/kg  
LOAEL : 2 mg/kg  
Application Route : Oral  
Exposure time : 1 y  
Target Organs : Gastrointestinal tract, Bone, Blood

Species : Monkey  
NOAEL : 0,05 mg/kg  
Exposure time : 1 y  
Target Organs : Gastrointestinal tract, Bone, Blood

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species : Rat  
NOAEL : 25 mg/kg  
Application Route : Oral  
Exposure time : 67 Weeks

Species : Dog  
NOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 54 Weeks  
Target Organs : Kidney

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Product:**

Eye contact : Symptoms: The most common side effects are:, bitter taste, burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hypertension, Nausea, upper respiratory tract infection

**Components:****Dorzolamide:**

Eye contact : Symptoms: burning or stinging of the eye, Blurred vision, tearing, asthenia, bitter taste, Nausea, dry mouth, Headache

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Eye contact : Symptoms: burning or stinging of the eye, dryness of the eyes, Headache, Nausea, Dizziness, dry mouth, changes in libido, hair loss, Allergic reactions  
Ingestion : Symptoms: Headache, Fatigue, Respiratory disorders, Gastrointestinal discomfort, Allergic reactions, Rash, hair loss, altered mental status, Dizziness, changes in libido

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Dorzolamide:**

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 699 mg/l  
Exposure time: 48 h

Toxicity to microorganisms : EC50 (Natural microorganism): > 800 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 411 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 161 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

EC50 (Photobacterium phosphoreum): > 1.800 mg/l

**Persistence and degradability****Components:****Dorzolamide:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 5 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 30 d

Stability in water : Hydrolysis: 0 % (61 d)  
Method: FDA 3.09

**Bioaccumulative potential****Components:****Dorzolamide:**

Partition coefficient: n-octanol/water : log Pow: 0,292

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Partition coefficient: n-octanol/water : log Pow: 1,48

**Timolol / Dorzolamide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

octanol/water

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry.	:	Not applicable
---	---	----------------

Control of precursors and essential chemicals for the preparation of drugs.	:	Not applicable
---	---	----------------

**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
------	---	----------------

DSL	:	not determined
-----	---	----------------

IECSC	:	not determined
-------	---	----------------

## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

## SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023  
Date format : dd.mm.yyyy

## Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

## Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.13	30.09.2023	28787-00021	Date of first issue: 06.11.2014

---

AR / Z8